Singlon 10mg 28 tablets — Made in Hungary — Free Delivery

Treatment of bronchial asthma

Prevention of exercise-induced bronchospasm in patients over 15 years of age.

Relief of symptoms of seasonal and perennial allergic rhinitis.

Hypersensitivity to montelukast or to any of the excipients of the preparation.

Age up to 15 years.

Interaction with other medicinal products and other types of interactions.

active substance: montelukast

1 chewable tablet of 10 mg contains 10 mg of montelukast (in the form of sodium montelukast - 10.4 mg)

excipients: mannitol (E 421), microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, cherry flavor (maltodextrin, modified starch, maltol), aspartame (E 951), iron oxide yellow (E172), magnesium stearate.

The dose for patients (over the age of 15) suffering from bronchial asthma or bronchial asthma with concomitant seasonal allergic rhinitis is 10 mg (1 tablet) 1 time per day, in the evening, regardless of the meal. To alleviate the symptoms of allergic rhinitis, the time of use of the preparation should be selected individually.

The therapeutic effect of Singlon on bronchial asthma control indicators lasts 1 day. The preparation can be used regardless of food intake. Patients should be advised to continue taking Singlon even if they achieve control of the symptoms of bronchial asthma, as well as during periods of exacerbation of bronchial asthma.

Singlon should not be used with other products containing the same active ingredient - montelukast

Elderly patients, patients with renal insufficiency or hepatic insufficiency of mild or moderate severity do not require dose adjustment. There are no data on patients with severe hepatic impairment. Doses of the preparation for men and women are the same.

Treatment with Singlon, depending on other methods of treating bronchial asthma.

Singlon can be added to an existing course of treatment for a patient.

Inhaled corticosteroids: Singlon can be used as an adjunct treatment for patients who do not achieve satisfactory clinical control of the disease by using inhaled corticosteroids in combination with short-acting

Singlon is not a harsh substitute for inhaled corticosteroids.

The preparation Singlon, film-coated tablets, 10 mg, should be used in children aged 15 years and older.

For children under 15 years old, use the preparation Singlon, chewable tablets 4 mg, and Singlon, chewable tablets, 5 mg each.

Safety and efficacy in children under 2 years of age have not been established.